Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.40 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | CTSH | P09668 | 2/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727416 | 1.00 | CTSK (0.43) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL10442075 | 1.00 | CTSK (0.43) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL20342111 | 0.98 | CTSK (0.41) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL12220087 | 0.98 | CTSK (0.41) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL13909105 | 0.98 | CTSK (0.41) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL14898377 | 0.94 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL12220084 | 0.94 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL13127846 | 0.94 | CTSK (0.37) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL24233279 | 0.90 | GRN (0.36) | CTSKCTSLCTSBCTSHGRN | |
| SCHEMBL8291760 | 0.90 | GRN (0.36) | CTSKCTSLCTSBCTSHGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535397-B1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | ARROWHEAD PHARMACEUTICALS INC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | disclosed |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-04-24 | — | — | US | disclosed |
| EP-1603598-B1 | RADIOLABELED CONJUGATES BASED ON SUBSTANCE P AND THE USES THEREOF | UNIVERSITAETSSPITAL BASEL (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20070053837-A1 | Radiopharmaceuticals for cancer diagnosis and treatment | KANTONSSPITAL BASEL (CH) | 2007-03-08 | — | — | US | disclosed |
| US-20070053837-A1 | Radiopharmaceuticals for cancer diagnosis and treatment | KANTONSSPITAL BASEL (CH) | 2007-03-08 | — | — | US | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | UTS2R, SCTR, PLAUR | CTSK 556/4885CTSL 150/4885CTSB 501/4885 |
| US-20070053837-A1 | Radiopharmaceuticals for cancer diagnosis and treatment | TACR1, GRPR, SSTR1 | CTSK 294/4885CTSL 390/4885CTSB 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.